GW9662, a potent antagonist of PPAR[gamma], inhibits growth of breast tumour cells and promotes the anticancer effects of the PPAR[gamma] agonist rosiglitazone, independently of PPAR[gamma] activation

• Published in: British journal of pharmacology Vol. 143; no. 8; p. 933
• Main Authors: Seargent, Jill M, Yates, Elisabeth A, Gill, Jason H
• Format: Journal Article
• Language: English
• Published: London Blackwell Publishing Ltd 01.12.2004
• ISSN: 0007-1188; 1476-5381
• DOI: 10.1038/sj.bjp.0705973

Peroxisome proliferator-activated receptor gamma (PPARgamma), a member of the nuclear receptor superfamily, is activated by several compounds, including the thiazolidinediones. In addition to being a therapeutic target for obesity, hypolipidaemia and diabetes, perturbation of PPARgamma signalling is now believed to be a strategy for treatment of several cancers, including breast. Although differential expression of PPARgamma is observed in tumours compared to normal tissues and PPARgamma agonists have been shown to inhibit tumour cell growth and survival, the interdependence of these observations is unclear. This study demonstrated that the potent, irreversible and selective PPARgamma antagonist GW9662 prevented activation of PPARgamma and inhibited growth of human mammary tumour cell lines. Controversially, GW9662 prevented rosiglitazone-mediated PPARgamma activation, but enhanced rather than reversed rosiglitazone-induced growth inhibition. As such, these data support the existence of PPARgamma-independent pathways and question the central belief that PPARgamma ligands mediate their anticancer effects via activation of PPARgamma.